Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. Academic Article uri icon

Overview

abstract

  • Patient-reported outcomes (PROs) can inform treatment selection and assess treatment value in acute myeloid leukemia (AML). We evaluated PROs from the ADMIRAL trial (NCT02421939) in patients with FLT3-mutated relapsed/refractory (R/R) AML. PRO instruments consisted of Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu), Functional Assessment of Chronic Illness Therapy-Dyspnea Short Form (FACIT-Dys SF), EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and leukemia treatment-specific symptom questionnaires. Clinically significant effects on fatigue were observed with gilteritinib during the first two treatment cycles. Shorter survival was associated with clinically significant worsening of BFI, FACT-Leu, FACIT-Dys SF, and EQ-5D-5L measures. Transplantation and transfusion independence in gilteritinib-arm patients were also associated with maintenance or improvement in PROs. Health-related quality of life remained stable in the gilteritinib arm. Hospitalization had a small but significant effect on patient-reported fatigue. Gilteritinib was associated with a favorable effect on fatigue and other PROs in patients with FLT3-mutated R/R AML.

authors

  • Ritchie, Ellen K.
  • Cella, David
  • Fabbiano, Francesco
  • Pigneux, Arnaud
  • Kanda, Yoshinobu
  • Ivanescu, Cristina
  • Pandya, Bhavik J
  • Shah, Manasee V

publication date

  • April 5, 2023

Research

keywords

  • Leukemia, Myeloid, Acute
  • Quality of Life

Identity

Digital Object Identifier (DOI)

  • 10.1080/10428194.2023.2186731

PubMed ID

  • 37019445